Treatment Regimen for Tuberculosis Diagnosed Using TRUENAT

Understanding TRUENAT as a Diagnostic Tool

TRUENAT is a chip-based real-time PCR test that detects Mycobacterium tuberculosis in sputum samples, providing results with a fast turnaround time of 35-50 minutes, and has minimal biosafety requirements as samples are collected in viral lysis medium 2
TRUENAT has been proven to be a rapid, portable, and cost-effective test for TB diagnosis within primary healthcare facilities 2

The American Academy of Family Physicians recommends a standard treatment regimen for tuberculosis diagnosed using TRUENAT, consisting of isoniazid, rifampin, pyrazinamide, and ethambutol for the initial 2 months, followed by isoniazid and rifampin for 4 months 1
The American Journal of Respiratory and Critical Care Medicine guidelines suggest daily administration of four drugs, including isoniazid, rifampin, pyrazinamide, and ethambutol, with weight-based dosing for rifampin, pyrazinamide, and ethambutol 3
The treatment duration may be extended to 9 months if cavities were seen on initial chest radiograph and culture remains positive after 2 months of treatment, as recommended by the American Journal of Respiratory and Critical Care Medicine 3

The American Journal of Respiratory and Critical Care Medicine recommends that HIV-infected patients may require longer treatment durations, and three-times weekly regimen is recommended for HIV patients with CD4 counts <100/μl 4
The European Respiratory Journal suggests considering therapeutic drug monitoring due to potential malabsorption issues in HIV-infected patients 5
For MDR-TB, an all-oral bedaquiline-containing regimen is preferred, and treatment must be individualized based on drug susceptibility testing results, as recommended by the European Respiratory Journal 5

The American Journal of Respiratory and Critical Care Medicine recommends repeat sputum smear and culture after 2 months of treatment, and if culture remains positive at 2 months and cavitation was present on initial chest radiograph, extend continuation phase to 7 months (total 9 months) 3
Monitoring for adverse effects of medications, such as hepatotoxicity and visual disturbances with ethambutol, is also recommended by the American Journal of Respiratory and Critical Care Medicine 3

The Clinical Infectious Diseases journal warns against not confirming drug susceptibility before initiating treatment, and using inadequate regimens that may lead to development of drug resistance 6
The American Journal of Respiratory and Critical Care Medicine also warns against not adjusting treatment duration based on clinical and microbiological response, and not recognizing potential drug interactions, particularly with rifampin which induces cytochrome P450 enzymes 3